Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma

Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the most common fatal malignancies and the main cause of cancer-related deaths. The multitarget tyrosine kinase inhibitors (TKIs) sorafenib and regorafenib are systemic therapeutic drugs approved for the treatment of HCC. Here, we found that sorafenib and reg...

Full description

Bibliographic Details
Main Authors: Shun Zhang, Yixin Wang, Yifan Cao, Jin Wu, Zubin Zhang, Haigang Ren, Xiaohui Xu, Elena Kaznacheyeva, Qing Li, Guanghui Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Pharmacology
Subjects:
HCC
sorafenib
regorafenib
MPTP
PINK1
mitophagy
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.851832/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.851832/full

Similar Items